1. Home
  2. TVTX vs FBNC Comparison

TVTX vs FBNC Comparison

Compare TVTX & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • FBNC
  • Stock Information
  • Founded
  • TVTX 2008
  • FBNC 1934
  • Country
  • TVTX United States
  • FBNC United States
  • Employees
  • TVTX N/A
  • FBNC N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • FBNC Major Banks
  • Sector
  • TVTX Health Care
  • FBNC Finance
  • Exchange
  • TVTX Nasdaq
  • FBNC Nasdaq
  • Market Cap
  • TVTX 1.5B
  • FBNC 2.1B
  • IPO Year
  • TVTX N/A
  • FBNC N/A
  • Fundamental
  • Price
  • TVTX $23.11
  • FBNC $54.37
  • Analyst Decision
  • TVTX Strong Buy
  • FBNC Buy
  • Analyst Count
  • TVTX 16
  • FBNC 4
  • Target Price
  • TVTX $35.20
  • FBNC $56.67
  • AVG Volume (30 Days)
  • TVTX 2.7M
  • FBNC 196.4K
  • Earning Date
  • TVTX 10-30-2025
  • FBNC 10-22-2025
  • Dividend Yield
  • TVTX N/A
  • FBNC 1.69%
  • EPS Growth
  • TVTX N/A
  • FBNC N/A
  • EPS
  • TVTX N/A
  • FBNC 2.35
  • Revenue
  • TVTX $333,865,000.00
  • FBNC $361,053,000.00
  • Revenue This Year
  • TVTX $83.26
  • FBNC $36.85
  • Revenue Next Year
  • TVTX $43.19
  • FBNC $8.45
  • P/E Ratio
  • TVTX N/A
  • FBNC $23.24
  • Revenue Growth
  • TVTX 87.94
  • FBNC N/A
  • 52 Week Low
  • TVTX $12.91
  • FBNC $34.50
  • 52 Week High
  • TVTX $28.69
  • FBNC $56.45
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 62.20
  • FBNC 52.19
  • Support Level
  • TVTX $22.52
  • FBNC N/A
  • Resistance Level
  • TVTX $28.69
  • FBNC $55.52
  • Average True Range (ATR)
  • TVTX 1.45
  • FBNC 0.90
  • MACD
  • TVTX 0.33
  • FBNC -2.27
  • Stochastic Oscillator
  • TVTX 52.05
  • FBNC 96.32

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About FBNC First Bancorp

First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.

Share on Social Networks: